The acquisition of the bioprocessing analytics portfolio from 908 Devices is likely to enhance Repligen's product offerings and capabilities in real-time process monitoring and control. This strategic move could positively impact Repligen's market position and revenue potential, leading to a likely short-term positive impact on its stock price.